The U.S. Food and Drug Administration on Friday approved Stemline Therapeutics Inc’s Elzonris for the treatment of a rare blood disease in adults and children aged two years and above.
U.S. FDA approves Stemline Therapeutics’ rare blood disease treatment
More from Pharma NewsMore posts in Pharma News »
- Brazil coronavirus deaths climb to 46,510, cases near 1 million
- Requiring masks ‘political hazard’ as COVID-19 surges in California breadbasket
- Mothers as ‘trauma surgeons:’ the anguish of raising black boys in America
- Record spike in new coronavirus cases reported in six U.S. states as reopening accelerates